Elevated Maternal Glycated Albumin is Associated with Large for Gestational Age Infants: Results from a Prospective Longitudinal Study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Aims/hypothesis

Glycated albumin (GA) has been shown to be a moderate predictor of gestational diabetes mellitus (GDM), while evidence supporting its role in predicting adverse pregnancy outcomes remains limited. Here, we aimed to perform a comparative study of GA and haemoglobin A1c (HbA 1c ) for predicting GDM and large-for-gestational-age (LGA) infants in a prospective cohort.

Methods

We developed a rapid liquid chromatography-tandem mass spectrometry method for measuring site-specific albumin glycation. GA was quantified at two glycation sites, GA (KQT) and GA (KLV), as well as their sum, GA-total. GA was measured in stored serum samples collected at 11-14 and 23-31 gestational weeks from 465 participants in the single-centre observational cohort. HbA 1c was measured routinely at each visit. Linear mixed-effects models were used to compare GA between participants with and without GDM (n=100) or LGA (n=57). Logistic regression was used to estimate odds ratios (ORs) for GDM and LGA according to GA and HbA 1c .

Results

GA was lower in women who developed GDM during early pregnancy compared to non-GDM controls (GA-total; p =0.004), while in mid-late pregnancy, only GA (KQT) was lower in women with GDM ( p =0.036). In contrast, HbA 1c was higher in women with GDM at both timepoints compared to non-GDM controls ( p <0.001) and higher HbA 1c was associated with increased odds of GDM (OR=2.20, p <0.001; OR=2.30, p <0.001, respectively). GA was higher in the LGA group, in both early (GA-total; p =0.032) and mid-late pregnancy (GA-total; p =0.030) and associated with increased odds of LGA (GA-total; OR=1.59, p =0.009; GA-total; OR=1.46, p =0.019, respectively). HbA 1c was not associated with LGA at either timepoint.

Conclusions/interpretation

Higher GA in early and mid-late pregnancy were associated with an increased risk of LGA, whereas no significant association was observed for HbA 1c . GA may therefore provide risk assessment beyond HbA 1c for identifying pregnancies at risk of fetal overgrowth.

Research in Context

What is already known about this subject?

  • Glycated albumin (GA) has been proposed as a biomarker for GDM, LGA, and other adverse pregnancy outcomes.

  • HbA 1c is an established marker of chronic glycaemia outside pregnancy, but its role in the routine diagnosis and monitoring of GDM during pregnancy remains limited.

  • Both GA and HbA 1c are markers of glycaemic exposure; however, they capture different time frames and are influenced differently by the physiological changes of pregnancy.

What is the key question?

  • Are GA and HbA 1c measured during pregnancy associated with GDM and LGA?

What are the new findings?

  • HbA 1c and GA showed opposing associations with GDM development.

  • Higher GA in early and mid-late pregnancy were associated with an increased risk of LGA.

  • HbA 1c showed limited association with LGA.

How might this impact clinical practice in the foreseeable future?

  • GA and HbA 1c may serve as complementary biomarkers for assessing glycaemia and predicting pregnancy complications, with potential utility for improving risk stratification during pregnancy.

Article activity feed